Press Releases

11.24.2015

Merck KGaA, Darmstadt, Germany, and Pfizer Receive Positive Opinion for Orphan Drug Designation for Avelumab in Merkel Cell Carcinoma from EMA Committee for Orphan Medicinal Products

11.24.2015

Pfizer Receives European Approval to Expand Use of XALKORI® (crizotinib) to First-Line Treatment of Adults with ALK-Positive Advanced Non-Small Cell Lung Cancer

11.23.2015

Pfizer And Allergan To Combine

11.18.2015

Thermo Fisher Scientific Signs Development Agreement for Next-Generation Sequencing-Based Companion Diagnostic

11.18.2015

Pfizer Reports Positive Topline Results from Phase 3 Trial Comparing XALKORI® (crizotinib) to Chemotherapy in Previously Untreated East Asian Patients with ALK-Positive Advanced Non-Small Cell Lung Cancer (NSCLC)

11.18.2015

Merck KGaA, Darmstadt, Germany, and Pfizer Receive FDA Breakthrough Therapy Designation for Avelumab in Metastatic Merkel Cell Carcinoma

11.15.2015

Global Partners Announce Donation of 500 Millionth Dose of Azithromycin, Marking Exceptional Progress to Help Alleviate the Suffering from Trachoma

11.10.2015

Uwe Schoenbeck from Pfizer Inc. appointed member of CQDM’s Board of Directors

11.06.2015

Bristol-Myers Squibb and Pfizer to Present New Data on Eliquis (apixaban) at the American Heart Association (AHA) Scientific Sessions 2015

11.05.2015

Pfizer Expands its Patient Assistance Program, Doubling the Income Eligibility Limit to Benefit Even More Patients Taking Pfizer Medicines

11.05.2015

Global Analysis Of Metastatic Breast Cancer Landscape Reveals Gaps In Patient Care And Support

11.04.2015

Merck KGaA, Darmstadt, Germany, and Pfizer Announce Initiation of Phase III First-Line Trial of Avelumab in Patients with Recurrent or Stage IV Non-Small Cell Lung Cancer